Search

Displaying results 9121 - 9130 of 9347 in total
  1. Drug

    LGD-1550

    go.drugbank.com/drugs/DB05785
    Experimental

    LGD-1550 is an orally-active synthetic aromatic retinoic acid agent with potential antineoplastic and chemopreventive activities.

  2. Drug

    Zansecimab

    go.drugbank.com/drugs/DB16389
    Investigational

    Zansecimab is under investigation in clinical trial NCT04342897 (A Study of LY3127804 in Participants With COVID-19).

  3. Drug

    ATL1102

    go.drugbank.com/drugs/DB04997
    Investigational

    ATL1102 is a second-generation antisense inhibitor of CD49d, an immunesystem protein known as VLA-4, an immune cell molecule. It works by entering cells and targeting genes.

  4. Drug

    Boldenone undecylenate

    go.drugbank.com/drugs/DB14639
    ExperimentalIllicitVet approved

  5. Drug

    ASI402

    go.drugbank.com/drugs/DB06373
    Investigational

    ASI402 is a monoclonal antibody that targets an aberrantly glycosylated antigen Mucin 1. It is being investigated in cancers.

  6. Drug

    Cefpiramide

    go.drugbank.com/drugs/DB00430
    Approved

    Cefpiramide is a third-generation cephalosporin antibiotic.

  7. Drug

    CERE-110

    go.drugbank.com/drugs/DB05898
    Investigational

    CERE-110 is a gene-therapy product that involves in vivo delivery of nerve growth factor (NGF) genes through an adeno-associated viral vector (AAV) delivery system. This drug is developed by Ceregene and currently under phase I of clinic...

  8. Drug

    Acetylcysteine zidrimer

    go.drugbank.com/drugs/DB16496
    Investigational

  9. Drug

    Sapacitabine

    go.drugbank.com/drugs/DB06365
    Investigational

  10. Drug

    RI 624

    go.drugbank.com/drugs/DB05892
    Experimental

    RI 624 is a novel humanized monoclonal antibody that blocks nerve growth factor (NGF), a key mediator of acute and chronic pain. RI 624 is being developed by Rinat and is currently in Phase I clinical trials.